# Effect of DPP4 Inhibition on Growth Hormone Secretion

> **NCT01701973** · PHASE4 · COMPLETED · sponsor: **Vanderbilt University** · enrollment: 44 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Pegvisomant
- **DRUG:** Placebo
- **DRUG:** L-NMMA
- **DRUG:** Exendin 9-39

## Key facts

- **NCT ID:** NCT01701973
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2018-05-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01701973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01701973, "Effect of DPP4 Inhibition on Growth Hormone Secretion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01701973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*